Status:
COMPLETED
Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles
Lead Sponsor:
Allergan
Conditions:
Periorbital Hyperpigmentation
Eligibility:
All Genders
25-50 years
Brief Summary
This study will evaluate the physiopathologic characteristics of dark circles in participants with various ethnicities and Fitzpatrick Skin Types and the impact of the dark circles on the quality of l...
Eligibility Criteria
Inclusion
- Participants with Fitzpatrick skin type I-VI
- Willingness to not wear any eye makeup on the day of the study visit prior to the study visit appointment
- Willingness to cleanse the face and remove all makeup at least 15 minutes prior to each scheduled clinic visit
- Willingness to have facial exams, skin instrumentation measurements, and digital photos performed on the face.
Exclusion
- Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring, tattoos, or other skin conditions in the test area
- Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune
- Individuals who have a pre-existing or dormant dermatologic condition (e.g. history of severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
- Individuals who have had a blepharoplasty procedure or any other surgery in proximity or affecting the test area
- Individuals with recent procedures/surgeries (less than 6 months) on the eye bulb
- Individuals with permanent makeup around the eye area
- Chemical peel, microdermabrasion, microneedling, or dermaplaning in the previous 4 weeks
- Latisse, Revitalash, or other lash enhancement stimulators in the previous 1 month
- Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, Avage® or Differin® or other similar prescription drugs within the previous 3 months
- Cosmetic injections (filler and/or toxins, i.e.Juvederm, Radiesse, Botox, etc.), non- ablative laser or fractional laser resurfacing in the previous 12 months
- Accutane® or other oral retinoid, Ablative procedures (i.e. laser, chemical) in the previous 12 months
- Individuals who have any planned surgeries or procedures during the study.
Key Trial Info
Start Date :
February 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 7 2018
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT03400202
Start Date
February 2 2018
End Date
November 7 2018
Last Update
January 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SkinMedica Clinical Research and Innovation Center
Irvine, California, United States, 92612